Rolipram attenuates MK-801-induced deficits in latent inhibition

Behavioral Neuroscience

Volumn 119, Issue 2, 2005, Pages 595-602

  Davis, Jennifer A ^a   Gould, Thomas J ^a  

^a TEMPLE UNIVERSITY   (United States)

Author keywords

Attention; cAMP; Phosphodiesterase; PKA; Schizophrenia

Indexed keywords

CYCLIC AMP; DIZOCILPINE; ROLIPRAM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUDITORY STIMULATION; BEHAVIOR DISORDER; COGNITIVE DEFECT; CONDITIONING; CONTROLLED STUDY; LATENT INHIBITION; MALE; MOUSE; NONHUMAN; SCHIZOPHRENIA; SHOCK; SIGNAL TRANSDUCTION; TRAINING;

ANIMALS; CYCLIC AMP; DISEASE MODELS, ANIMAL; DIZOCILPINE MALEATE; EXCITATORY AMINO ACID ANTAGONISTS; INHIBITION (PSYCHOLOGY); MALE; MICE; MICE, INBRED C57BL; PHOSPHODIESTERASE INHIBITORS; REACTION TIME; RECEPTORS, N-METHYL-D-ASPARTATE; ROLIPRAM; SCHIZOPHRENIA; SIGNAL TRANSDUCTION;

EID: 17444381935     PISSN: 07357044     EISSN: None     Source Type: Journal    
DOI: 10.1037/0735-7044.119.2.595     Document Type: Article

References (86)

1. Abel, T., & Kandel, E. (1998). Positive and negative regulatory mechanisms that mediate long-term memory storage. Brain Research Reviews, 26, 360-378.
2. Abel, T., & Lattal, K. M. (2001). Molecular mechanisms of memory acquisition, consolidation, and retrieval. Current Opinions in Neurobiology, 11, 180-187.
3. Abel, T., Nguyen, P. V., Barad, M., Deuel, T. A. S., Kandel, E. R., & Bourtchouladze, R. (1997). Genetic demonstration of a role for PKA in the late phase of LTP and in hippocampus-based long-term memory. Cell, 88, 615-626.
4. Aguado, L., San Antonio, A., Perez, L., Del Valle, R., & Gomez, J. (1994). Effects of NMDA receptor antagonist ketamine on flavor memory: Conditioned taste aversion, latent inhibition, and habituation of neophobia. Behavioral and Neural Biology, 61, 271-281.
5. Bach, M. E., Barad, M., Son, H., Zhuo, M., Lu, M., Shih, R., et al. (1999). Age-related defects in spatial memory are correlated with defects in the late phase of hippocampal long-term potentiation in vitro and are attenuated by drugs that enhance the cAMP signaling pathway. Proceedings of the National Academy of Sciences, USA, 96, 5280-5285.
6. Barad, M., Bourtchouladze, R., Winder, D. G., Golan, H., & Kandel, E. (1998). Rolipram, a type IV-specific phosphodiesterase inhibitor, facilitates the establishment of long-lasting long-term potentiation and improves memory. Proceedings of the National Academy of Sciences, USA, 95, 15020-15025.
7. Beavo, J. A. (1988). Multiple isozymes of cyclic nucleotide phosphodiesterase. Advances in Second Messenger and Phosphodiesterase Research, 22, 1-38.
8. Becker, A., Peters, B., Schroder, H., Mann, T., Huether, G., & Grecksch, G. (2003). Ketamine-induced changes in rat behaviour: A possible animal model of schizophrenia. Progress in Neuro-Psychopharmacology & Biological Psychiatry, 27, 687-700.
9. Bourtchouladze, R., Lidge, R., Catapano, R., Stanley, J., Gossweiler, S., Romashko, D., et al. (2003). A mouse model of Rubinstein-Taybi syndrome: Defective long-term memory is ameliorated by inhibitors of phosphodiesterase 4. Proceedings of the National Academy of Sciences, USA, 100, 10518-10522.
10. Boutros, N. N., Beiger, A., Campbell, D., D'Souza, C., & Krystal, J. (1999). Comparison of four components of sensory gating in schizophrenia and normal subjects: A preliminary report. Psychiatry Research, 88, 119-130.
11. Braff, D. L. (1993). Information processing and attention dysfunctions in schizophrenia. Schizophrenia Bulletin, 19, 233-259.
12. Breese, G. R., Knapp, D. J., & Moy, S. S. (2002). Integrative role for serotonergic and glutamatergic receptor mechanisms in the action of NMDA antagonists: Potential relationships to antipsychotic drug action on NMDA antagonist responsiveness. Neuroscience & Biobehavioral Reviews, 26, 441-455.
13. Carlsson, A., Waters, N., & Carlsson, M. L. (1999). Neurotransmitter interactions in schizophrenia - Therapeutic implications. Biological Psychiatry, 46, 1388-1395.
14. Charriaut-Marlangue, C., Dessi, F., & Ben-Ari, Y. (1994). Inhibition of protein synthesis by NMDA channel blocker MK-801. NeuroReport, 5, 1110-1112.
15. 2+ channel activity in area CA1 of the hippocampus. Proceedings of the National Academy of Sciences, USA, 88, 6467-6471.
16. Coutureau, E., Blundell, P. J., & Killcross, S. (2001). Basolateral amygdala lesions disrupt latent inhibition in rats. Brain Research Bulletin, 56, 49-53.
17. DeLapp, N. W., & Eckols, K. (1992). Forskolin stimulation of cyclic AMP accumulation in rat brain cortex slices is markedly enhanced by endogenous adenosine. Journal of Neurochemistry, 58, 237-242.
18. Donaldson, J., Brown, A. M., & Hill, S. J. (1988). Influence of rolipram on the cyclic 3′, 5′ adenosine monophosphate response to histamine and adenosine in slices of guinea-pig cerebral cortex. Biochemical Pharmacology, 37, 715-723.
19. Dudai, Y. (1983). Mutations affect storage and use of memory differentially in Drosophila. Proceedings of the National Academy of Sciences, USA, 80, 5445-5448.
20. Dunn, L. A., Atwater, G. E., & Kilts, C. D. (1993). Effects of antipsychotic drugs on latent inhibition: Sensitivity and specificity of an animal behavioral model of clinical drug action. Psychopharmacology, 112, 315-323.
21. Freedman, R., Adler, L. E., Olincy, A., Waldo, M. C., Ross, R. G., Stevens, K. E., et al. (2002). Input dysfunction, schizotypy, and genetic models of schizophrenia. Schizophrenia Research, 54, 25-32.
22. Gaisler-Salomon, I., & Weiner, I. (2003). Systemic administration of MK-801 produces an abnormally persistent latent inhibition which is reversed by clozapine but not haloperidol. Psychopharmacology, 166, 333-342.
23. Gallo, M., Bielayska, E., Roldan, G., & Bures, J. (1998). Tetrodotoxin inactivation of the gustatory cortex disrupts the effect of the N-methyl-D-aspartate antagonist ketamine on latent inhibition of conditioned taste aversion in rats. Neuroscience Letters, 240, 61-64.
24. Goda, Y., & Stevens, C. F. (1996). Synaptic plasticity: The basis of particular types of learning. Current Biology, 6, 375-378.
25. sα. Neuropsychopharmacology, 29, 494-501.
26. Gould, T. J., Collins, A. C., & Wehner, J. M. (2001). Nicotine enhances latent inhibition and ameliorates ethanol-induced deficits in latent inhibition. Nicotine & Tobacco Research, 3, 17-24.
27. Gould, T. J., McCarthy, M. M., & Keith, R. A. (2002). MK-801 disrupts acquisition of contextual fear conditioning but enhances memory consolidation of cued fear conditioning. Behavioural Pharmacology, 13, 287-294.
28. Gould, T. J., & Wehner, J. M. (1999). Genetic influences on latent inhibition in mice. Behavioral Neuroscience, 113, 1291-1296.
29. Gray, J. A., Feldon, J., Rawlins, J. N. P., Hemsley, D. R., & Smith, A. D. (1991). The neuropsychology of schizophrenia. Behavioural Brain Science, 14, 1-84.
30. Han, J. S., Gallagher, M., & Holland, P. (1995). Hippocampal lesions disrupt decrements but not increments in conditioned stimulus processing. Journal of Neuroscience, 15, 7323-7329.
31. Harrison, P. J. (1999). The neuropathology of schizophrenia: A critical review of the data and their interpretation. Brain, 122, 593-624.
32. Hirsch, S. R., Das, I., Garey, L. J., & de Belleroche, J. (1997). A pivotal role for glutamate in the pathogenesis of schizophrenia, and its cognitive dysfunction. Pharmacology Biochemistry and Behavior, 56, 797-802.
33. Huang, E. P. (1998). Synaptic plasticity: Going through phases with LTP. Current Biology, 8, R350-R352.
34. Imanishi, T., Sawa, A., Ichimaru, Y., Miyashiro, M., Kato, S., Yamamoto, T., et al. (1997). Ameliorating effects of rolipram on experimentally induced impairments of learning and memory in rodents. European Journal of Pharmacology, 321, 273-278.
35. 3H]2-deoxyglucose uptake in mouse brain and heart in vivo. European Journal of Nuclear Medicine, 29, 1212-1215.
36. 3H]rolipram. Brain Research, 503, 229-245.
37. Kaye, H., & Pearce, J. M. (1987). Hippocampal lesions attenuate latent inhibition and the decline of the orienting response in rats. Quarterly Journal of Experimental Psychology: Comparative and Physiological Psychology, 39(B), 107-125.
38. Kelly, M. P., Tocarczyk, J., Rappaport, D. A., Godfrey, M., Kanes, S. J., & Abel, T. (2003, November). Modeling cognitive deficits of schizophrenia in mice with altered g-protein signaling [Abstract]. Poster session presented at the annual meeting of the Society for Neuroscience (Program No. 858.2). Retrieved from http://sfn.scholarone.com/itin2003.html
39. Kilts, C. D. (2001). The changing roles and targets for animal models of schizophrenia. Biological Psychiatry, 50, 845-855.
40. Krause, K., & Kuhne, G. (1988). Pharmacokinetics of rolipram in the rhesus and cynomolgus monkeys, the rat and the rabbit: Studies on species differences. Xenobiotica, 18, 561-571.
41. Lattal, K. M., & Abel, T. (2000). Cellular and molecular mechanisms of learning and memory. In M. E. A. Reith (Ed.), Cerebral signal transduction: From first to fourth messengers (pp. 3-47). Totowa, NJ: Humana Press.
42. Lewis, M. C., & Gould, T. J. (2004). Latent inhibition of cued fear conditioning: An NMDA receptor-dependent process that can be established in the presence of anisomycin. European Journal of Neuroscience, 20, 818-826.
43. Loughney, K., Snyder, P. B., Uher, L., Rosman, G. J., Ferguson, K., & Florio, V. A. (1999). Isolation and characterization of PDE10A, a novel human 3′, 5′-cyclic nucleotide phosphodiesterase. Gene, 234, 109-117.
44. 11C]Ro 20-1724 in rats. Synapse, 31, 41-50.
45. 11C]rolipram for PET imaging of phosphodiesterase-4: In vivo binding, metabolism, and dosimetry studies in rats. Nuclear Medicine and Biology, 28, 347-358.
46. Lubow, R. E., & Gerwirtz, J. C. (1995). Latent inhibition in humans: Data, theory, and implications for schizophrenia. Psychological Bulletin, 117, 87-103.
47. Lubow, R. E., Kaplan, O., Abramovich, P., Rudnick, A., & Laor, N. (2000). Visual search in schizophrenia: Latent inhibition and novel pop-out effects. Schizophrenia Research, 45, 145-156.
48. Lubow, R. E., Weiner, I., & Feldon, J. (1982). An animal model of attention. In M. Y. Spiegelstein & A. Levy (Eds.), Behavioral models and the analysis of drug action (pp. 89-107). New York: Elsevier.
49. McLaurin, W. A., Farley, J. A., & Scarborough, B. B. (1963). Inhibitory effect of preirradiation saccharin habituation on conditioned avoidance behavior. Radiation Research, 18, 473-478.
50. Mehats, C., Anderson, C. B., Filopanti, M., Jin, C. S.-L., & Conti, M. (2002). Cyclic nucleotide phosphodiesterases and their role in endocrine cell signaling. Trends in Endocrinology & Metabolism: Clinical and Experimental, 13, 29-35.
51. Moser, P. C., Hitchcock, J. M., Lister, S., & Moran, P. M. (2000). The pharmacology of latent inhibition as an animal model of schizophrenia. Brain Research Reviews, 33, 275-307.
52. Nagakura, A., Niimura, M., & Takeo, S. (2002). Effects of phosphodiesterase IV inhibitor rolipram on microsphere embolism-induced defects in memory function and cerebral cyclic AMP signal transduction system in rats. British Journal of Pharmacology, 135, 1783-1793.
53. Nguyen, P. V., Abel, T., & Kandel, E. R. (1994, August 19). Requirement of a critical period of transcription for induction of late phase of LTP. Science, 265, 1104-1107.
54. Nguyen, P. V., & Woo, N. H. (2003). Regulation of hippocampal synaptic plasticity by cyclic AMP-dependent protein kinases. Progress in Neurobiology, 71, 401-437.
55. O'Donnell, J. M., & Frith, S. (1999). Behavioral effects of family-selective inhibitors of cyclic nucleotide phosphodiesterases. Pharmacology Biochemistry and Behavior, 63, 185-192.
56. Olney, J. W., Newcomer, J. W., & Farber, N. B. (1999). NMDA receptor hypofunction model of schizophrenia. Journal of Psychiatric Research, 33, 523-533.
57. Oswald, C. J., Yee, B. K., Rawlins, J. N., Bannerman, D. B., Good, M., & Honey, R. C. (2002). The influence of selective lesions to components of the hippocampal system on the orienting [correction of orienting] response, habituation and latent inhibition. European Journal of Neuroscience, 15, 1983-1990.
58. Palsson, E., Klamer, D., Wass, C., Trevor, A., Engel, J. A., & Svensson, L. (in press). The effects of phencyclidine on latent inhibition in taste aversion conditioning: Differential effects of preexposure and conditioning. Behavioural Brain Research.
59. 2+-stimulated adenylyl cyclases in LTP and memory formation. International Journal of Developmental Neuroscience, 19, 387-394.
60. Pouzet, B., Zhang, W. N., Weiner, I., Feldon, J., & Yee, B. K. (2004). Latent inhibition is spared by N-methyl-D-aspartate (NMDA)-induced ventral hippocampal lesions, but is attenuated following local activation of the ventral hippocampus by intracerebral NMDA infusion. Neuroscience, 124, 183-194.
61. Randt, C. T., Judge, M. E., Bonnet, K. A., & Quartermain, D. (1982). Brain cyclic AMP and memory in mice. Pharmacology Biochemistry and Behavior, 17, 677-680.
62. Rascle, C., Mazas, O., Vaiva, G., Tournant, M., Raybois, O., Goudemand, M., & Thomas, P. (2001). Clinical features of latent inhibition in schizophrenia. Schizophrenia Research, 51, 149-161.
63. Reidel, G., Platt, B., & Micheau, J. (2003). Glutamate receptor function in learning and memory. Behavioural Drain Research, 140, 1-47.
64. Rybalkin, S. D., & Beavo, J. A. (1996). Multiplicity within cyclic nucleotide phosphodiesterases. Biochemical Society Transactions, 24, 1005-1009.
65. Schauz, C., & Koch, M. (2000). Blockade of NMDA receptors in the amygdala prevents latent inhibition of fear-conditioning. Learning & Memory, 7, 393-399.
66. Schmajuk, N. A., Christiansen, B., & Cox, L. (2000). Haloperidol reinstates latent inhibition impaired by hippocampal lesions: Data and theory. Behavioral Neuroscience, 114, 659-670.
67. Schmajuk, N. A., Lam, Y. W., & Christiansen, B. A. (1994). Latent inhibition of the rat eyeblink response: Effect of hippocampal aspiration lesions. Physiological Behavior, 55, 596-601.
68. Schneider, H. H., Schmiechen, R., Brezinski, M., & Seidler, J. (1986). Stereospecific binding of the antidepressant rolipram to brain protein structures. European Journal of Pharmacology, 127, 105-115.
69. Schroeder, U., Schroeder, H., Darius, J., Grecksch, G., & Sabel, B. A. (1998). Simulation of psychosis by continuous delivery of phencyclidine from controlled-release polymer implants. Behavioural Brain Research, 97, 59-68.
70. Selcher, J. C., Weeber, E. J., Varga, A. W., Sweatt, J. D., & Swank, M. (2002). Protein kinase signal transduction cascades in mammalian associative conditioning. The Neuroscientist, 8, 122-131.
71. Shiigi, Y., & Casey, D. E. (1999). Behavioral effects of ketamine, an NMDA glutamatergic antagonist, in non-human primates. Psychopharmacology, 146, 67-72.
72. Silvestre, J. S., Fernandez, A. G., & Palacios, J. M. (1999). Effects of rolipram on the elevated plus-maze test in rats: A preliminary study. Journal of Psychopharmacology, 13, 274-277.
73. Soderling, S. H., & Beavo, J. A. (2000). Regulation of cAMP and cGMP signaling: New phosphodiesterases and new functions. Current Opinion in Cell Biology, 12, 174-179.
74. Stone, E. A., & John, S. M. (1990). In vivo measurement of extracellular cyclic AMP in the brain: Use in studies of β-adrenoreceptor function in nonanesthetized rats. Journal of Neurochemistry, 55, 1942-1949.
75. Swerdlow, N. R., Braff, D. L., Hartston, H., Perry, W. P., & Geyer, M. A. (1996). Latent inhibition in schizophrenia. Schizophrenia Research, 20, 91-103.
76. Szapiro, G., Vianna, M. R. M., McGaugh, J. L., Medina, J. H., & Izquierdo, I. (2003). The role of NMDA glutamate receptors, PKA, MAPK, and CAMKII in the hippocampus in extinction of conditioned fear. Hippocampus, 13, 53-58.
77. Tardito, D., Maina, G., Tura, G. B., Bogetto, F., Pioli, R., Ravizza, L., et al. (2001). The cAMP-dependent protein kinase substrate Rap I in platelets from patients with obsessive compulsive disorder or schizophrenia. European Neuropsychopharmacology, 11, 221-225.
78. Tardito, D., Tura, G. B., Bocchio, L., Bignotti, S., Pioli, R., Racagni, G., et al. (2000). Abnormal levels of cAMP-dependent protein kinase regulatory subunits in platelets from schizophrenic patients. Neuropsychopharmacology, 23, 216-219.
79. Traverso, L. M., Ruiz, G., & De la Casa, L. G. (2003). Latent inhibition disruption by MK-801 in a conditioned taste-aversion paradigm. Neurobiology of Learning and Memory, 80, 140-146.
80. Turgeon, S. M., Auerbach, E. A., Duncan-Smith, M. K., George, J. R., & Graves, W. W. (2000). The delayed effects of DTG and MK-801 on latent inhibition in a conditioned taste-aversion paradigm. Pharmacology Biochemistry and Behavior, 66, 533-539.
81. Turgeon, S. M., Auerbach, E. A., & Heller, M. A. (1998). The delayed effects of phencyclidine (PCP) disrupt latent inhibition in a conditioned taste aversion paradigm. Pharmacology Biochemistry and Behavior, 60, 553-558.
82. Vaitl, D., Lipp, O., Bauer, U., Schuler, G., Stark, R., Zimmermann, M., et al. (2002). Latent inhibition and schizophrenia: Pavlovian conditioning of autonomic responses. Schizophrenia Research, 55, 147-158.
83. Weiner, I. (2003). The "two-headed" latent inhibition model of schizophrenia: Modeling positive and negative symptoms and their treatment. Psychopharmacology, 169, 255-297.
84. Weiner, I., & Feldon, J. (1992). Phencyclidine does not disrupt latent inhibition in rats: Implications for animal models of schizophrenia. Pharmacology Biochemistry and Behavior, 42, 625-631.
85. Zhang, H.-T., Crissman, A. M., Dorairaj, N. R., Chandler, L. J., & O'Donnell, J. M. (2000). Inhibition of cyclic AMP phosphodiesterase (PDE4) reverses memory deficits associated with NMDA receptor antagonism. Neuropsychopharmacology, 135, 1783-1793.
86. Zhang, H.-T., & O'Donnell, J. M. (2000). Effects of rolipram on scopolamine-induced impairment of working and reference memory in the radial-arm maze tests in rats. Psychopharmacology, 150, 311-316.